JP2001523635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001523635A5 JP2001523635A5 JP2000514634A JP2000514634A JP2001523635A5 JP 2001523635 A5 JP2001523635 A5 JP 2001523635A5 JP 2000514634 A JP2000514634 A JP 2000514634A JP 2000514634 A JP2000514634 A JP 2000514634A JP 2001523635 A5 JP2001523635 A5 JP 2001523635A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- subject
- period
- dichloroacetate
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940120124 Dichloroacetate Drugs 0.000 description 5
- JXTHNDFMNIQAHM-UHFFFAOYSA-M dichloroacetate Chemical compound [O-]C(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-M 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000036868 Blood Concentration Effects 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Description
【特許請求の範囲】
【請求項１】
心機能不良症状を有するまたは心機能不良の危険性を有する被験体に、ボーラス投与とその後の１時間よりも長い期間にわたる持続的投与を含み、それにより該被験体のジクロロアセテート血中濃度が１時間よりも長い期間にわたって約５００μＭ以上となるような条件で、ジクロロアセテート溶液を送達することを含む方法において使用するための医薬の製造におけるジクロロアセテート溶液の使用。
【請求項２】
前記被験体が成人である、請求項１記載の使用。
【請求項３】
前記被験体が小児である、請求項１記載の使用。
【請求項４】
前記被験体が乳児である、請求項１記載の使用。
【請求項５】
前記被験体が新生児である、請求項１記載の使用。
【請求項６】
前記被験体が心臓手術を受け、術後に前記送達が行われる、請求項１記載の使用。
【請求項７】
前記ボーラスが約１００ｍｇ／ｍｌ溶液の少なくとも１００ｍｇ／ｋｇを含む、請求項６記載の使用。
【請求項８】
前記持続的投与が約１２．５ｍｇ／ｋｇ／時で１０時間よりも長い期間にわたる注入を含む、請求項７記載の使用。
【請求項９】
前記送達によりジクロロアセテート血中濃度が１０時間よりも長い期間にわたり１ｍＭより高くなる、請求項８記載の使用。
【請求項１０】
前記持続的投与が約１２．５ｍｇ／ｋｇ／時で１時間よりも長い期間にわたる注入を含む、請求項１記載の使用。
【請求項１１】
前記送達によりジクロロアセテート血中濃度が１０時間よりも長い期間にわたり１ｍＭより高くなる、請求項１記載の使用。
【請求項１２】
心機能不良が心臓手術に関連する、請求項１〜１１のいずれか１項に記載の使用。
[Claims]
(1)
A subject having a cardiac dysfunction symptom or at risk of cardiac dysfunction includes a bolus dose followed by a continuous dose over a period of more than one hour, whereby the subject has a dichloroacetate blood concentration of 1%. Use of a dichloroacetate solution in the manufacture of a medicament for use in a method comprising delivering a dichloroacetate solution under conditions such that it is greater than or equal to about 500 μM over a period of time greater than time.
(2)
The use according to claim 1, wherein the subject is an adult.
(3)
The use according to claim 1, wherein the subject is a child.
(4)
The use according to claim 1, wherein the subject is an infant.
(5)
The use according to claim 1, wherein the subject is a newborn.
6.
The use according to claim 1, wherein the subject has undergone cardiac surgery and the delivery is performed post-operatively.
7.
7. The use according to claim 6, wherein said bolus comprises at least 100 mg / kg of about 100 mg / ml solution.
Claim 8.
9. The use of claim 7, wherein said continuous administration comprises an infusion at about 12.5 mg / kg / hr for a period of more than 10 hours.
9.
9. Use according to claim 8, wherein said delivery results in a blood dichloroacetate concentration of greater than 1 mM for a period of longer than 10 hours.
10.
The use according to claim 1, wherein the continuous administration comprises an infusion at about 12.5 mg / kg / hr for a period of more than 1 hour .
11.
The use according to claim 1, wherein the delivery results in a dichloroacetate blood concentration of greater than 1 mM over a period of more than 10 hours.
12.
12. Use according to any one of the preceding claims, wherein the cardiac dysfunction is associated with cardiac surgery.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6091297P | 1997-10-03 | 1997-10-03 | |
| US60/060,912 | 1997-10-03 | ||
| PCT/US1998/020394 WO1999017763A1 (en) | 1997-10-03 | 1998-09-30 | Postsurgical treatment with dichloroacetate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001523635A JP2001523635A (en) | 2001-11-27 |
| JP2001523635A5 true JP2001523635A5 (en) | 2006-01-05 |
Family
ID=22032515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000514634A Pending JP2001523635A (en) | 1997-10-03 | 1998-09-30 | Postoperative treatment with dichloroacetate |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2001523635A (en) |
| AU (1) | AU9590698A (en) |
| CA (1) | CA2305183C (en) |
| WO (1) | WO1999017763A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6727284B2 (en) | 1997-10-03 | 2004-04-27 | University Of Alberta | Postsurgical treatment with dichloroacetate |
| BR0205721A (en) | 2001-07-06 | 2003-09-30 | Endo Pharmaceuticals Inc | Controlled Release Oxymorphone Formulations |
| EP1517705B1 (en) * | 2002-06-20 | 2008-05-21 | The Governors Of The University Of Alberta | Dichloroacetate in combination with cardioprotective or hemodynamic drugs |
| EP1908462A3 (en) * | 2002-06-20 | 2008-06-25 | The Governors Of The University Of Alberta | Dichloroacetate in combination with cardioprotective or hemodynamic drugs |
| US20060194878A1 (en) * | 2002-10-07 | 2006-08-31 | Lopaschuk Gary D | Methods of cardioprotection using dichloroacetate in combination with an inotrope |
| US6693133B1 (en) | 2002-10-07 | 2004-02-17 | University Of Alberta | Methods of cardioprotection using dichloroacetate in combination with an inotrope |
| AU2004315552A1 (en) * | 2004-01-16 | 2005-08-25 | The Governors Of The University Of Alberta | Dichloroacetate in combination with an inotrope for cardioprotection |
| US9765393B2 (en) | 2010-06-14 | 2017-09-19 | University Of Florida Research Foundation, Inc. | Methods, assays, and kits related to dichloroacetate (DCA) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0786993B1 (en) * | 1994-10-17 | 2002-06-05 | Peter W. Stacpoole | Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and their use in the treatment of metabolic and cardiovascular disorders |
| US5587397A (en) * | 1995-06-08 | 1996-12-24 | Cypros Pharmaceutical Corporation | Reduction of elevated blood lactate using twice-daily dichloroacetate |
-
1998
- 1998-09-30 JP JP2000514634A patent/JP2001523635A/en active Pending
- 1998-09-30 CA CA002305183A patent/CA2305183C/en not_active Expired - Fee Related
- 1998-09-30 AU AU95906/98A patent/AU9590698A/en not_active Abandoned
- 1998-09-30 WO PCT/US1998/020394 patent/WO1999017763A1/en active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Skogsdal et al. | Analgesia in newborns given oral glucose | |
| Jacqz-Aigrain et al. | Placebo-controlled trial of midazolam sedation in mechanically ventilated newborn babies | |
| GR3031448T3 (en) | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine. | |
| Routledge | Pharmacokinetics in children | |
| Schirrmacher | Case of cobalt poisoning. | |
| Mathieson et al. | Central pontine myelinolysis with other cerebral changes: A report of 2 cases | |
| JP2533874B2 (en) | Method of treating addicted individuals using human growth hormone | |
| JP2001523635A5 (en) | ||
| Evans et al. | Intraosseous infusion—a technique available for intravascular administration of drugs and fluids in the child with burns | |
| Acocella et al. | Serum and urine concentrations of rifampicin administered by intravenous infusion in man | |
| Darendeliler et al. | Long-Term Diazoxide Treatment in Persistent Hyperinsulincmic Hypoglycemia of Infancy: A Case Report | |
| Lai et al. | Burning-Feet Syndrome: Case Due to Malabsorption and Responding to Riboflavine | |
| Handley | Heparin administration by constant infusion pump. | |
| DiRaimondo et al. | Remarkable sensitivity to insulin in a patient with hypopituitarism and diabetic acidosis | |
| Brogden et al. | Alfathesin (‘Althesin’—Glaxo): An Independent Report | |
| CHENG | Nocturnal enuresis and psychotropic drugs | |
| Rossetti | Single-shot vs conventional therapy with amikacin for treatment of uncomplicated urinary tract infections: a multicenter study | |
| Hambleton et al. | We showed the letter from Dr. D'Souza to Dr. Davies and Dr. Hambleton, who replied as follows | |
| D'Souza | Intramuscular versus oral phenytoin. | |
| Lee | The management of the patient under peridural anesthesia | |
| FINCH et al. | Methohexitone 5 per cent: evaluation using an experimental pain generator | |
| US5684047A (en) | 4-guanidinobutyramide for improving blood circulation | |
| Schneider | Side Effects of Diphenylhydantoin in Childhood | |
| SULLIVAN | Early GH Corrects Growth in Turner Syndrome | |
| Marks et al. | Hypertensive encephalopathy and desoxycorticosterone |